AliveDx Suisse S.A. and Palex Medical S.A.U. have signed a distribution agreement, which will enable Palex to distribute the MosaiQ® solution in Spain. The distribution agreement takes effect immediately.
This partnership reaffirms AliveDx’s commitment to expanding its geographical presence and creating clinical and economical value for clinicians, helping them to shorten the time to diagnosis. It will enable both parties to introduce new quality services to the healthcare industry and enhance patient care in Spain.
The MosaiQ platform simplifies workflows and creates efficiencies thanks to its multiplexing microarray assay technology. This streamlined and efficient approach offers faster and more cost-effective solutions to healthcare providers and patients alike.
“Our partnership with Palex enables us to demonstrate our commitment to transforming patient care on a global scale. We look forward to partnering with them and supporting the Spanish healthcare system with our fast and innovative disease detection solutions,” said Manuel O. Méndez, AliveDx’s CEO.
The Palex Group is the largest European provider of value-added solutions and services for healthcare, science, and research. Its mission is to support healthcare and research professionals by giving them access to technological innovations and tailoring them to their needs to help them change lives. Founded in 1955 and headquartered in Barcelona, Spain, it operates in the Spanish, Portuguese, and Italian markets with a team of over 1,000 professionals integrated into various highly specialized companies.
“Through this partnership with AliveDx, Palex integrates the innovative MosaiQ multiplexing microarray assay technology into its portfolio, offering a comprehensive solution in the field of autoimmune diagnostics,” said Jaume Clariana, IVD Specialized Unit Leader.
To learn more, please visit the Palex Medical website.
